Senti Biosciences Files 8-K

TL;DR

Senti Bio filed an 8-K with financial docs, nothing major yet.

AI Summary

On December 2, 2024, Senti Biosciences, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and a Regulation FD disclosure. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This 8-K filing indicates Senti Biosciences is providing updated financial statements and exhibits, which is a standard regulatory requirement for public companies.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, with no immediate indication of significant negative events.

Key Players & Entities

• Senti Biosciences, Inc. (company) — Registrant
• December 2, 2024 (date) — Date of Report
• 2 Corporate Drive, First Floor (address) — Principal Executive Offices
• South San Francisco, CA 94080 (address) — Principal Executive Offices
• 001-40440 (other) — Commission File Number

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share SNTI The Nasdaq Capital M

Filing Documents

• ef20039399_8k.htm (8-K) — 31KB
• ef20039399_ex99-1.htm (EX-99.1) — 40KB
• image00001.jpg (GRAPHIC) — 2KB
• 0001140361-24-048114.txt ( ) — 225KB
• snti-20241202.xsd (EX-101.SCH) — 4KB
• snti-20241202_lab.xml (EX-101.LAB) — 22KB
• snti-20241202_pre.xml (EX-101.PRE) — 16KB
• ef20039399_8k_htm.xml (XML) — 4KB

01

Item 7.01. Regulation FD Disclosure. On December 2, 2024, Senti Biosciences, Inc. (the "Company") issued a press release announcing initial clinical data from a Phase 1 clinical trial of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer investigational cell therapy, for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia ("AML"). SENTI-202 is designed to selectively target and eliminate CD33 and/or FLT3- expressing hematologic malignancies, including AML, while sparing healthy bone marrow cells. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 7.01 of Form 8-K, including the accompanying Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing. Cautionary Note Regarding Forward Looking Statements This Current Report on Form 8-K and other related materials may contain a number of "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the Company's expectation about any or all of the following: timing of its clinical trials for SENTI-202; the timing of availability of data from the ongoing Phase 1 clinical trial of SENTI-202; as well as the ability of any product candidate to perform in humans in a manner consistent with nonclinical, preclinical or previous clinical study data. Forward-looking

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by the Company on December 2, 2024, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Senti Biosciences, Inc. Date: December 2, 2024 By: /s/ Timothy Lu Timothy Lu, M.D., Ph.D. Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR